Efanesoctocog alfa
- Generic Name
- Efanesoctocog alfa
- Brand Names
- Altuviiio, Altuvoct
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2252477-42-0
- Unique Ingredient Identifier
- WH7BHQ0RB4
- Background
Efanesoctocog alfa (BIVV001) is a recombinant factor VIII (FVIII) analogue fusion protein used for the routine prophylaxis, perioperative management of bleeding and on-demand treatment and control of bleeding episodes in patients with hemophilia A. The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of li...
- Indication
Efanesoctocog alfa is indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding.
- Associated Conditions
- Bleeding, Perioperative Blood Loss, Bleeding episodes
- Associated Therapies
- -
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 78
- Registration Number
- NCT06716814
- Locations
- 🇪🇸
Sobi Investigational Site, Zaragoza, Spain
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 120
- Registration Number
- NCT06684314
- Locations
- 🇨🇳
Investigational Site Number : 1580008, Changhua, Taiwan
🇨🇳Investigational Site Number : 1580010, Kaohsiung, Taiwan
🇨🇳Investigational Site Number : 1580005, Taichung, Taiwan
Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 24
- Registration Number
- NCT06579144
- Locations
- 🇩🇪
Sobi Investigational site, Frankfurt, Germany
🇪🇸Sobi Investigational Site, Zaragoza, Spain
Goal Attainment and Physical Activity in People With Hemophilia A
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT06530030
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 93
- Registration Number
- NCT05817812
- Locations
- 🇬🇧
Investigational Site, Oxford, United Kingdom
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT05042440
- Locations
- 🇧🇬
Investigational Site Number :1000001, Sofia, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.